Four Premaitha (NIPT) bods presented and faced the music at the UK Investor City forum last week. I was hard on them with my questions as were other members of the audience. But I think they coped well and the shares are most certainly a BUY. Enjoy the video and remember that the next forum (featuring Sosandar) is on 3 December. We will start taking bookings next week.
Tom Winnifrith writes: For the second time Premaitha (NIPT) has served up a trading update for the six months to 30 September and thus having heard the news before it is hardly shocking. FFS do its PR folks think we are stupid or what? Answering my own question, the self important, over-paid, halfwitted knobheads probably do.
There are now just the last 5 ( of 120) places left for the next Wray family organised UK Investor evening seminar in central London. So if you want to book a slot do so now HERE. The event kicks off with drinks and canapes from 5.30 with the first talk just after six. It will be a packed evening.
I am looking forward to grilling Premaitha (NIPT) at the Nigel Wray London seminar on 16 October. There are still a few places going and its free – details HERE. Meanwhile we have three pieces of news this week following that rather disappointing placing at 10p two Friday's ago caused by the a’hole behaviour of the toads at FinnCap. Yes this is Tom Winnifrith writing…
Under promise and over deliver is what PR poltroons tell their AIM clients. So you say you are looking to raise x but know you will raise x and a bit and then call it a massive success even if the placing is only at 66% of the share price a week or so earlier.
Tom Winnifrith writes and has also discussed this in bearcast HERE: We ordinary shareholders in Premaitha (NIPT) have suffered for many years and shown enormous loyalty. News released well after the market close of a £2.5 million placing at 10p might thus seem like a kick in the teeth by a management treating us with contempt. I am afraid the story is far worse.
We have only been waiting three years for this and in the end it came as a complete surprise but a very pleasant one at that. At last Premaitha (NIPT) has settled its patent dispute with American bully boy giants Illumina. This bolt from the blue is great news and now means that a rapidly growing and profitable business will be, at last, valued on fundamentals and that will drive a re-rate which appears to be underway already.
We are getting increasingly used to Premaitha (NIPT) announcing more and more large non-UK distribution agreements. And fear not there will be much more on that front in the weeks and months that lie ahead. It will be a hot summer for Premaitha and for we loyal shareholders. But, for now, there is something a bit different.
The rehabilitation of Premaitha Health (NIPT) continues. The latest news is from India where there is not even a whiff of a patent challenge from Illumina and where our boys have signed a 3-year agreement with one of the most advanced clinical laboratory groups in the country to provide a bespoke, high quality and scaleable NIPT solution.
Let's declare an interest first. FIML, a company owned via a Trust by dependents of Tom Winnifrith, took part in the placing at 4.5p but was scaled back so topped up with market purchases at 6.9p.
It is the house broker so not impartial. I think the target for Premaitha (NIPT) is too low and bought more shares this morning in the secondary market. But here is the Finncap take in a 20 page note:
Premaitha Health (NIPT) has announced an exclusive partner agreement to offer the IONA non-invasive prenatal test across Egypt and a first Egyptian customer…
Premaitha Health (NIPT) has announced that its IONA test has been approved by Brazil's regulatory authority, Agência Nacional de Vigilância Sanitária (ANVISA), for sale as an in vitro diagnostic test.
Updating on Premaitha Health (NIPT) earlier in the week we noted an up to £2.1 million loan facility agreement to fund costs related to the ongoing Illumina litigation and that a Form of Order hearing is scheduled to take place early this week. The shares are currently rising towards 5p on the back of a UK High Court grants right to appeal announcement from the company…
On last month-announced results for its half year ended 30th September 2017, we noted Premaitha Health (NIPT) currently looking at positive pre-litigation cashflows, but that there remained risk of low cash headroom or even a cash shortfall including if further litigation-related costs are required. There’s now a Secured loan facility agreement with Thermo Fisher announcement.
Results for its half-year ended 30th September 2017 from Premaitha Health (NIPT) contained some bad news – which sees the shares currently at a depressed little more than 5p, but also many more positive aspects…
After the Illumina legal setback for Premaitha (NIPT) we suggested that the cost of that setback was very manageable – a maximum of less than £2 million is what we hear – and that the underlying business is doing very well. That view is reaffirmed by latest news.
This is not the news we Premaitha (NIPT) shareholders wanted and it is clearly bad news. The question is how bad? The UK High Court has upheld three patent claims made by Illumina against Premaitha.
Premaitha (NIPT) has announced that it has been approved for Brazilian Good Manufacturing Practice for the company's IONA test by Brazil's regulatory authority, the Agência Nacional de Vigilância Sanitária. Jolly good news and it strengthens the story, but it is not the elephant in the room is it?
Premaitha Health (NIPT) has announced that it has entered into a further extension of the investment agreement with Thermo Fisher Scientific announced on 14 December 2015 and extended as announced on 23 September 2016. This is good news.
And so after more than a year of huff and puff and fascist corporate bullying by US giant Illumina, the High Court action with Premaitha (NIPT) starts tomorrow. Premaitha says:
Premaitha (NIPT) has updated investors on its progress in India where it claims now to have representation in 9 of the 15 most populous states with several of the largest nationwide pathology laboratory groups running Yourgene's NIPT workflow in-house.
Premaitha (NIPT) has updated on trading in the year to March 31 2017. Of course, what matters is not historic trading but the future, that is to say the patent challenge by US corporate fascist bully-boys Ilumina. However, some numbers do matter...
The issue with Genoma was flagged up in the interims pre-Christmas. It owes Premaitha (NIPT) £750,000. That debt looks like a bad debt because the Swiss company has - despite its parent company concluding a fundraise - been having financial issues. So Premaitha has gone to court and had Genoma made bankrupt.
We have a new share tip out at 2PM today but here is one which has not dazzled yet. We tipped it an an 18p offer, the shares are now 11.75p-12.5p but we hope readers took our advice and averaged down at as low as 7.5p But the stock is now on a roll and is still cheap. You can catch our new hot tip for just £5 HERE but pro tem back to Premaitha (NIPT).
The fragrant Alice Lane, a foxy young brokerette who apparently I once reduced to tears by being so beastly, is this morning disseminating the latest FinnCap note on Premaitha (NIPT) to clients. Since it is bullish I am happy to make it up to Alice by exposing this high quality research to a wider audience, especially since we own more than a few shares. By way of balance i should say that FinnCap is house broker and therefore utterly partial and you can feel free to ignore every word of this report.
After two pieces of good news in as many days you do not need to be cynic of the year to expect a placing. But this is not a placing as in the company's broker goes and grovels to fund managers. Premaitha (NIPT) was approached and asked it wanted cash and so has taken £1.487 million at 8.75p per share from Harwood Capital
After a longish period of radio silence Premaitha (NIPT) has served up news of a number of new customers through its distribution network in Southern Europe.
Premaitha (NIPT) has announced that its Thai distributor. Geneplus, has formally signed an agreement to offer the Company's IONA test in the Center for Medical Genomics (CMG), Ramathibodi Hospital, Mahidol University, partnering with the Thailand Center of Excellence for Life Sciences.
Hello Share Keepers. There were interesting responses to my piece which followed Uncle Tom’s thoughts on Premaitha (NIPT). And there’s probably a bit more to say on the wider picture of buying shares in companies which are doing things you may be uneasy about for your own personal, moral reasons.
The Government has announced that as of 2018 it will offer free Non Invasive Prenatal Tests (NIPT) for Downs to women deemed to be at high risk - that is those over 38 years old. Right now it costs you £180 to have an NIPT test rather than an invasive one which has a 1% chance of killing your baby.
Hello Share Collectors. There is a Mel Gibson film being praised at the moment. It tells the story of a soldier in the Second World War who refused to kill, yet still went into battle to save his colleagues.
The Guardian has reported that as of 2018 the NHS will offer free non invasive tests for Downs to all at risk women. This is great news for AIM listed Premaitha (NIPT) which is a leading provider of such tests. For it there is a clear financial gain but there is an ethical element here which as a shareholder but also a recent father causes me some issues.
And now to what has not, to date, been a good share tip. But it will be and at 9p-9.25p you should average down in Premaitha (NIPT) and buy. The AGM statement this week from chairman Adam Reynolds was upbeat.
Premaitha (NIPT) announced late last week its results for the year to March 31 2016. Given the pace of events here these historic numbers do not mean that much but for the record:
Apologies for the delay in commenting on this RNS which landed on Friday. We wanted to speak to Adam Reynolds and we have now done so. This is just the start of the good news and ahead of results tomorrow Premaitha (NIPT) shares are a buy.
After 44 years of membership, at last one good thing has come out of the EU for Britain. God bless the Evil Empire. Premaitha (NIPT) has provided an update on its legal battles with US bully boys Illumina.
Finncap is joint broker to Premaitha (NIPT) so is clearly biased. We own shed loads of the shares so are we. So feel free to ignore it all but here is FinnCap's pretty detailed initiation of coverage note.
In the third Dragon's Den session at UK Investor Show the Dragons were myself (Tom Winnifrith) Steve Moore and Brian Kinane. The companies pitching were United Cacao (CHOC), Premaitha (NIPT), ECR Minerals (ECR), Forbidden Technology (FBT) and Asiamet Resources (ARS)
Although the twit who handles PR for Premaitha (NIPT) has again contrived to confuse the issue with some garbled press releases this morning there is actually some good news. Fire the idiot PR man and investors could get excited as they discover what is really going on.
This is an utter shambles from AIM-listed Premaitha (NIPT). If you are going to go to the trouble and (shareholders’) expense of putting out an RNS to highlight some paid-for ramping research by Hardman, at least get the bloody RNS right! Tom Winnifrith has already had a furious rant that the company’s Broker, finnCap, should be sacked. Is the same true of the PR genii behind today’s abject efforts?
The shares of Premaitha (NIPT) have been all over the shop since what was a cracking year end trading statement on Monday. The reason is the cackhanded disposal of Rupert Lywood's remaining 17.9% stake. We thought he was locked in following his last dump on 9 March and a statement signed off by broker Finncap. Weasel words. His shares were placed by Finncap at just 6.5p with directors taking some and solid institutions Helium, Henderson and Hargreave Hale taking the rest. The overhang is now gone but boy has it crushed the shares. Without Lywood's "assistance" since last summer we think the shares would be 20p today. But he is now out of the picture.
Tom Winnifrith was an insider which restricted him from explaining why shares in Premaitha (NIPT) have been weak of late. Now you can see. The company's largest shareholder Rupert Lywood is a total 100% prat
The wider market is taking a bath and Premaitha (NIPT) shares are not immune to this now at 14.5p-15p. But there are also a couple of points which are company specific and in that vein we have had a detailed chat with the company on Friday.
Premaitha Health (NIPT) has announced a partnering with Leeds Teaching Hospitals NHS Trust - one of the largest in England - to provide a private non-invasive prenatal screening service for pregnant women in the region.
Premaitha Health (NIPT) has announced further international expansion of its customer base and updated on UK litigation timing
Premaitha Health (NIPT) has welcomed the UK National Screening Committee recommendation to routinely offer non-invasive prenatal testing on the NHS to high-risk pregnant women, noting “this is the first time that non-invasive prenatal testing will be routinely available to high risk pregnant women on the NHS and sets a precedent that we expect other countries to follow in the near future” and that“Premaitha is uniquely positioned to bring the benefits of non-invasive prenatal testing to the NHS”
Today at the request of my small handful of readers I look at shares in Dechra Pharma (DPH), Frontera Resources (FRR) and Premaitha Health (NIPT) setting share price targets for all three stocks.
Premaitha Health (NIPT) has noted an announcement from Illumina, Inc. of patent infringement suits against Premaitha's customer in Poland and Ariosa Diagnostics, a subsidiary of Roche, and their customer, The Doctors Laboratory, in the UK, while reiterating that it “continues to make a robust defence against earlier claims by Illumina and the board is confident that the IONA test does not infringe the patents as claimed in the earlier cases or in relation to today's announcement”
Ok this was one of my less successful share tips of the year for 2015 but this time it really will come good. That will be the prompt for guffaws of laughter from Wildes, who is currently sitting on a sinking lifeboat from the doomed SS LGO Energy. But he who laughs last...
If you want me to analyse a stock for you just drop me a line at firstname.lastname@example.org - Today I look at shares in Anglo Asian Mining (AAZ), Fastnet Equity (FAST) and Premaitha Health (NIPT) setting share price targets for all three stocks.
Premaitha Health (NIPT) has announced results for its half year ended 30th September 2015, that “we have a good pipeline of prospects and we are confident that we will continue to build our revenues throughout the forthcoming period” and an up to £5 million loan facility from $17 billion revenue science company Thermo Fisher.
And now it is the shellmeister Adam Reynolds, he of Optibiotix (OPTI), New World Oil & Gas (NEW) and Premaitha (NIPT) fame presenting at Gold & Bears. A full interview by the Sith Lord with Adam is out today and can be read HERE. Enjoy the video.
Premaitha Health (NIPT) has announced Adgenix as its exclusive distributor in France and that Adgenix has already signed up its first laboratory customer - with a “contract for a minimum of three years to supply LaboSud with the IONA test”
Premaitha (NIPT) has announced some pretty stunning results from an independent test of its IONA test published in the Journal of Ultrasound, Obstetrics in Gynecology. Dam, why did we not get ahead of the news and subscribe to that must read publication? It sounds gripping stuff.
If you want me to analyse a stock for you just drop me a line at email@example.com - Today I look at shares in Ferrexpo (FXPO), Paragon Entertainment (PEL), Premaitha Health (NIPT), and setting share price targets for all three stocks
Premaitha Health (NIPT) has announced an agreement with the leading distributor of scientific products in Greece (Antisel SA) to provide its IONA test to clinical laboratories in the region and that it has been informed that American company Illumina, Inc. has added a third patent to its suit against it. Buy, sell or hold?
This was not going to be my tip in the recently published book "The Magnificent 7" which you can download for free HERE. I was set to tip Optibiotix (OPTI) at c40p. Unfortunately for you (but fortunately for me since we own shares in the company) the share price has raced ahead to a 48p offer. I still think that they could head much higher and Zak Mir reckons that Optibiotix shares will be 60p by October. I think, that is what a chartist terms a long term view.
Panmure Gordon is house broker to Premaitha (NIPT) so take its morning note with a pinch of salt. It is paid to say buy. However for what it is worth here is its analysis of today's news and its forecasts.
The Daily Mail & BBC this weekend ran stories about how the NHS was doing trials which would see all pregnant women getting a non invasive pre-natal test for down's syndrome. The Mail piece sums it up HERE
We have tipped Premaitha (NIPT) before and our readers have banked big gains on it Now the time is right for re-entry and so this Adam Reynolds biotech play was our second May share tip of the month.
If you want me to analyse a stock for you just drop me a line at firstname.lastname@example.org - Today I look at JKX Oil & Gas, Premaitha Health and RapidCloud International.
Last week was a bit of a stomach churner for Premaitha (NIPT). The shares zoomed for about 30 minutes as it announced a stunning deal to commercialise its IONA test. They the tanked as a US giant launched a patent infringement case. Today they are zooming – up 37% at 24p – but I am not selling. In fact I am just kicking myself for not buying more at 16p a week ago!
A few weeks earlier than we had expected, Premaitha Health (NIPT) has announced that it has received CE-mark approval for its Iona test and will therefore launch it commercially at once. This is good news and the shares are now 23.5p – 24.5p.
Premaitha (NIPT) has announced that it is almost there on getting the crucial CE-mark for its IONA test. It has passed two key milestones including ISO 13485:2003 certification which confirms that Premaitha's quality management system has been approved as applicable to the design, development and manufacture of in vitro diagnostic reagents and associated software for non-invasive assessment of genetic abnormalities.
One of the reasons that capitalism works while the alternative is doomed to fail is that failing companies can reinvent themselves.
Shares in Premaitha (NIPT) have slipped back to 17-17.5p as part of the pre Christmas non Santa rally. Results for the 7 months to 30 September were largely a Vialogy tidy up and were no great shakes. It is what will happen in 2015 that matters.
Today Pharma giant Roche has snapped up a California based form Ariosa which is big in what is termed NIPT. Panmure Gordon, house broker to Premaitha (NIPT) reckons this has a clear read across for its AIM listed client. In a note sent out today it writes:
Premaitha Health (NIPT) has updated investors attending its AGM that it believes its lead product “remains on target to be the first regulated CE marked ‘in vitro’ diagnostic product in the rapidly growing market for non-invasive prenatal screening”.
Panmure Gordon, house broker to Premaitha (NIPT) has initiated its coverage of the stock at 18.75p. It rates the shares as a buy with a 23p target, based on applying a 30% discount to a peer group analysis. The note from analyst Mike Mitchell is a detailed 23 page study.
Heck, I am biased, we own these shares, but I thought that the presentation by Stephen Little and Adam Reynolds of Premaitha (NIPT) at the first ShareProphets seminar was pretty compelling. I certainly view the shares as cheap on the basis of what I heard. To ensure that you get priority booking for future seminars (the next one on 13 October is now booked out but we will start taking bookings for 27 October next week) register HERE.
It sticks in the craw when management award themselves share options at 10p when the share price is 17p. But that is what Premaitha (NIPT) announced yesterday. However
AIM listed Premaitha (NIPT) was our share tip of the week two weeks ago at 10.75p – the shares are now 15.75p but are still a buy from here – we expect them to double by Christmas.
AIM listed Vialogy (VIY) was a perennial dog. That was all meant to change following the reversal of Premaitha into the business at 11p in July. So far the now renamed Premaitha Group (NIPT) has failed to sparkle. The shares are now 10.75p. But after a summer lull we reckon that is all about to change. Big time and soon. Hence it is our share tip of the week.
Search ShareProphets |
Recent Comments |